Details for New Drug Application (NDA): 203442
✉ Email this page to a colleague
The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.
Summary for 203442
| Tradename: | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE |
| Applicant: | Macleods Pharms Ltd |
| Ingredient: | emtricitabine; tenofovir disoproxil fumarate |
| Patents: | 0 |
Pharmacology for NDA: 203442
| Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 203442
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203442 | ANDA | NorthStar RxLLC | 16714-534 | 16714-534-01 | 30 TABLET, FILM COATED in 1 BOTTLE (16714-534-01) |
| EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203442 | ANDA | Macleods Pharmaceuticals Limited | 33342-106 | 33342-106-07 | 30 TABLET, FILM COATED in 1 BOTTLE (33342-106-07) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG;300MG | ||||
| Approval Date: | May 15, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
